Asunercept (APG101) and Cancer

A phase II, randomized study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma
Wick W et al., Clin Cancer Res 2014, 20(24):6304-6313

Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro
Merz C et al., Anticancer Drugs 2015, 26(7):716-727

CD95 promotes metastatic spread via Sck in pancreatic ductal adenocarcinoma
Teodorczyk M et al., Cell Death Differ 2015, 22(7): 1192–1202

 

Asunercept (APG101) and MDS

APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis
Raimbault A et al., Oncotarget 2016, 7(12):14898–14911 

 

Asunercept (APG101) and acute Graft-versus-Host Disease

Recombinant CD95-Fc (APG101) prevents graft-versus-host disease in mice without disabling antitumor cytotoxicity and T-cell functions
Hartmann N et al., Blood 2013, 121(3):556-565

 

Asunercept (APG101)– Phase I Data

Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients
Tuettenberg J et al., Int Immunopharmacol 2012, 13(1):93-100

 

HERA 

APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcγ receptors
Gieffers C et al., Mol Cancer Ther 2013, 12(12):2735-2747